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Abstract The aim of this study was to investigate the molecular
basis of human IgE^allergen interaction by screening a phage-
displayed peptide library with an allergen-specific human IgE-
mimicking monoclonal antibody (mAb). A mAb that reacted with
major grass pollen allergens was successfully identified and
shown to inhibit human IgE^allergen interaction. Biopanning of
a phage-displayed random peptide library with this mAb yielded
a 12 amino acid long mimotope. A synthetic peptide based on this
12-mer mimotope inhibited mAb and human IgE binding to grass
pollen extracts. Our results indicate that such synthetic peptide
mimotopes of allergens have potential as novel therapeutic
agents. ß 2001 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
Immediate hypersensitivity reactions to certain foreign pro-
teins, which can sometimes be fatal, are well known and docu-
mented [1]. This allergic response is due to histamine released
from mast cells and basophils as a result of cross-linking of
cell-bound immunoglobulin E (IgE) antibodies. Therefore, al-
lergen-speci¢c IgE antibodies serve as a valuable probe in
allergen identi¢cation and characterisation. Using such anti-
bodies, we and others have cloned and characterised a number
of clinically signi¢cant allergens [2] and mapped some of their
B cell [3] and T cell epitopes [4]. Further characterisation of
the molecular basis of the allergen^IgE interactions may allow
the design and production of synthetic haptens, based on such
areas of interaction, that block IgE cross-linking and thus
allow future development of novel therapeutics.
Allergy to grass pollen, which a¡ects up to 25^30% of the
population, has been reported frequently in the literature [5].
Among all grass types, rye grass pollen is the most clinically
signi¢cant in temperate climates of the world producing up to
half a tonne of pollen per hectare [6]. However, recent molec-
ular and immunological studies have shown a high degree of
cross-reactivity between taxonomically related grasses [2,7].
Such cross-reactivity is based on the occurrence of common
IgE-binding epitopes among similar allergens in di¡erent grass
pollens.
Current methods of allergy treatment are limited by safety
and e⁄cacy. For example, pharmacotherapy aims to neutral-
ise the e¡ects of the allergic reaction but is associated with a
number of side-e¡ects. On the other hand, allergen immuno-
therapy involves the periodic injection of allergen extracts, in
increasing doses, which carries a risk of systemic and annoy-
ing local reactions. There is a need for alternative approaches
to treatment. Allergen cross-reactivity not only simpli¢es di-
agnosis of grass pollen allergy but also could increase the
e⁄cacy of any potential therapeutic modalities that could be
directed to be e¡ective against several allergens.
One novel approach of investigating the molecular basis of
allergen^IgE interactions uses phage display peptide library
technology [8]. Phage-displayed peptide libraries allow for
the surface display of myriads of di¡erent combinations of
short stretches of amino acids (i.e. 7^12 residues in length)
that can be screened with a target molecule. Phage that inter-
act with the target molecule are then puri¢ed, ampli¢ed and
subjected to several rounds of further selections referred to as
‘biopanning’ [8]. The short DNA insert that encodes the sur-
face-displayed peptide is then sequenced and the amino acid
sequence of the mimotope determined. In this way, allergen-
speci¢c IgE antibodies can be used as the target molecule to
screen with the phage display peptide library to identify the
allergen mimotope involved in the reaction. Once the amino
acid sequence of the mimotope is determined, synthetic pep-
tides can be produced and their e¡ects as potential inhibitors
of allergen^IgE interactions evaluated.
Although useful and easily accessible, naturally occurring
human IgE antibodies are present in very low concentrations
and are polyclonal in nature, making it di⁄cult to use them as
the target molecule to investigate such interactions. Monoclo-
nal human IgE antibodies would be more desirable, but can-
not be prepared easily due to di⁄culties in Epstein^Barr virus
immortalisation of human B cells that produce IgE [9]. An
alternative target molecule is an allergen-speci¢c murine
monoclonal antibody (mAb), obtained using hybridoma tech-
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nology, that is immunologically similar to human IgE anti-
bodies; that is, it recognises the same epitope as human IgE
and therefore inhibits the allergen^IgE interaction. It has re-
cently been reported that such a strategy has been successful
with a murine mAb speci¢c to the major house dust mite
allergen Der p 1 [10].
We have identi¢ed a mAb that recognises major allergens of
a number of clinically signi¢cant grass pollens. We investi-
gated the ability of such a mAb to inhibit allergen^human
IgE interactions. Once characterised, we de¢ned the allergen
mimotopes for this selecting mAb using a phage display pep-
tide library. We studied the e¡ect of such mimotopes on the
allergen^mAb, and more importantly the allergen^human IgE
interactions, using inhibition immunoassays. We report here
the identi¢cation and immunological characterisation of the
novel allergen mimotope using this technology.
2. Materials and methods
2.1. Pollen extracts
Dry and de-fatted Lolium perenne (perennial rye-grass), Cynodon
dactylon (Bermuda grass), Sorghum halepense (Johnson grass), Dacty-
lis glomerata (orchard grass), Holcus lanatus (velvet grass), Poa pra-
tensis (Kentucky bluegrass), Festuca elatior (meadow fescue), Phleum
pratense (timothy grass), and Betula verrucosa (birch) pollen were
purchased from Greer Laboratories, Lenoir, NC, USA. Soluble pro-
teins from these pollen were obtained and their protein concentrations
determined as described elsewhere [11].
2.2. Patient sera
Human sera were obtained, with oral and written consent, from
grass pollen-allergic and non-allergic individuals attending the Allergy
Clinic at the Alfred Hospital. An allergic status was de¢ned by a
history of grass pollen allergy, positive skin prick test to grass pollen
and the presence of serum IgE speci¢c to grass pollen, as determined
by radioallergosorbent test.
2.3. mAb production
Six-week-old BALB/c mice were each injected intraperitoneally with
50 Wg of an equal mixture of total proteins from rye, Bermuda and
timothy grass pollens in Hunter’s Titermax adjuvant (CytRx, Athens,
GA, USA). After 14 days, a booster injection of the same amount of
protein mixture, without adjuvant, was administered. Ten days later,
sera of the mice were collected by eye bleeding and tested for grass
pollen reactivity via immunoblotting, as described below. Fifteen days
after this, the ¢nal boosters were injected and after 3 days mice were
killed. Their bloods were collected in 1.5-ml microfuge tubes and the
sera stored at 320‡C until required. Their spleens were dissected for
use in generation of hybridomas following established techniques [12].
Hybridomas were screened against the grass pollen proteins by en-
zyme-linked immunosorbent assay (ELISA) as described below. Pos-
itive hybridomas were selected for expansion and cloning following
standard methods [12]. Once cloned, the mAbs were tested by ELISA
and con¢rmed by Western immunoblotting against a panel of grass
pollen proteins. Since mAb 2A1 reacted with a number of allergens in
di¡erent grass pollen extracts, it was re-cloned in order to ensure the
monoclonal status of the cell line. mAb 2A1 was puri¢ed by protein G
chromatography (Pierce, Rockford, IL, USA), following the manufac-
turer’s instructions and used for biopanning and in inhibition immu-
noassays as described below.
2.4. Phage-displayed random peptide library screening
Puri¢ed mAb 2A1 (10 Wg/50 Wl/well in coating bu¡er) was immo-
bilised onto the walls of microtitre plate wells as described for ELISA
below. Biopanning of microtitre plate-coated mAb 2A1 with the PhD-
12 phage display peptide library kit (New England BioLabs, Beverly,
MA, USA) and characterisation of the binding clones was carried out
following the manufacturer’s instructions. Brie£y, 1.4U1011 pfu of
phage library (complexity = 1.9U109 transforming units), was exposed
to a plate coated with mAb 2A1, unbound phage were washed away
and the speci¢cally bound phage were eluted by lowering the pH. The
eluted pool of phage was ampli¢ed and the process was repeated for a
total of four rounds. After four rounds of biopanning, 10 individual
clones were isolated and sequenced as described below.
2.5. Mimotope sequencing and peptide synthesis
Pure phage DNA was used for direct sequencing employing the
[Q-32P]ATP end-labelled primer protocol of the fmol1, PCR-based
DNA sequencing system (Promega, Madison, WI, USA) according
to the manufacturer’s instructions. After the PCR sequencing reac-
tions were completed, the samples were heated at 75^80‡C for 2 min
and loaded onto a 6% polyacrylamide/7 M urea gel (Sequagel, Kim-
berly Research, NJ, USA) and the nucleotides were separated by elec-
trophoresis at a constant power of 40 W. The gel was transferred onto
Whatman 3 mm paper (Whatman, Maidstone, UK), dried at 80‡C
under vacuum and exposed to X-ray ¢lm (XAR, Kodak) overnight at
370‡C.
Peptide, based on the amino acid sequence of the mimotope, was
synthesised commercially using Fmoc chemistry and puri¢ed by high
pressure liquid chromatography (Auspep, Vic, Australia).
2.6. Mimotope sequence analysis
Amino acid sequences were deduced from the DNA sequences and
searched for comparison with other sequences in the Australian Na-
tional Genomic Information Service (ANGIS) database, which incor-
porates databases from the following major sources: GenBank,
EMBL, NBRF PIR protein and SwissProt libraries.
The frequency of amino acids present in the 10 peptides was com-
pared by M2 test with the frequency of amino acids in peptides derived
from the naive unpanned library as listed by the supplier (New Eng-
land BioLabs). The sequences of the peptides were aligned with each
other using the program PILEUP in conjunction with the Tudos
matrix which compares amino acids on the basis of physicochemical
properties [13,14]. Since the peptides are expressed at the amino-ter-
minus of pIII and therefore are structurally £exible, a low penalty for
the introduction of gaps was used. The peptides were then aligned as a
group with the sequences of the rye grass pollen allergens Lol p 1, Lol
p 2 and Lol p 5 to reveal patches of similarity with the target sequen-
ces.
2.7. Gel electrophoresis
Total grass pollen proteins (30 Wg/lane) and pre-stained molecular
weight markers (Life Technologies, USA; 10 Wl/lane) were resolved on
12.5% ‘mini’ sodium dodecyl sulphate^polyacrylamide gel electropho-
resis (SDS^PAGE) gels in a Xcell II Mini-Cell (Novex, CA, USA),
following the manufacturer’s instructions and as described previously
[11,15].
2.8. Western immunoblotting
SDS^PAGE gels containing total proteins of di¡erent grass pollens
were transferred onto nitrocellulose (NC) membranes (BA 0.45 Wm,
Schleicher and Schuell, Dassel, Germany) using Xcell II blotting ap-
paratus (Novex), following the manufacturer’s instructions. Following
immobilisation of proteins onto NC membranes, blots were blocked
in 10% w/v skim milk powder in phosphate-bu¡ered saline (PBS) and
probed with either mAb 2A1 (cell culture supernatant diluted 1:9,
5 ml/blot) or human sera containing IgE (serum pool of three grass
pollen-allergic individuals diluted 1:4, 5 ml/blot) following established
protocols [11]. Brie£y, the secondary antibody for detecting mAb 2A1
binding was horseradish peroxidase (HRP)-conjugated anti-mouse Igs
(Silenus, Australia) while human IgE binding was detected with rabbit
anti-human IgE (Dako, Denmark) followed by HRP-conjugated anti-
rabbit Ig (Promega). Hydrogen peroxide and the chromogen 4-chloro-
1-naphthol (Sigma, St. Louis, MO, USA) were used to visualise the
antibody binding sites on the blots [11]. All blots were incubated
together for up to 30 min to ensure relative development between
the di¡erent blots. Negative control blots were probed with a serum
pool of three non-allergic individuals while ‘no-serum/mAb’ controls
were probed with the secondary and/or tertiary detection antibodies
only. Negative control blots failed to demonstrate any antibody bind-
ing (data not shown).
2.9. ELISA
Total rye grass pollen proteins (10 Wg/well) in 50 Wl/well of coating
bu¡er (60 mM sodium bicarbonate/30 mM sodium carbonate, pH 9.3)
were used to coat ELISA microtitre plates at 4‡C overnight. After
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washing wells 10 times with 0.1% Tween 20 in PBS, the wells were
blocked with 1% bovine serum albumin (BSA) in PBS for 2 h at 37‡C.
After washing of all wells, the coated wells were incubated at 37‡C for
1 h with 50 Wl/well with either human serum (diluted 1:4) or mAb 2A1
(neat supernatant or diluted 1:9). After extensive washing, human
serum wells were incubated with 50 Wl/well of rabbit Ig to human
IgE (Dakopatts, CA, USA; diluted 1:750 in PBS/BSA) followed by
peroxidase-conjugated anti-rabbit Ig (Promega; diluted 1:2500 in
PBS/BSA) while mAb 2A1 wells were incubated with 50 Wl/well of
peroxidase-conjugated anti-mouse Ig (Amrad, Australia; diluted
1:500) for 1 h each at 37‡C, with extensive washing of all wells at
the end of each step. The plates were then incubated with 50 Wl/well of
peroxidase substrate (0.00024% w/v o-phenylenediamine, 0.0006%
H2O2 in distilled water) for 10 min at 37‡C and the reaction was
stopped with 25 Wl/well of 4 N H2SO4. The colour reaction was
then read at OD 492 nm. Negative control wells were incubated
either with a serum pool of three non-allergic individuals or with
the secondary and/or tertiary detection antibodies only (blank).
Negative controls failed to demonstrate any signi¢cant antibody bind-
ing and these values were deducted from the test values (data not
shown).
2.10. Inhibition immunoblot assay
Inhibition studies were conducted with NC blots, containing SDS^
PAGE-resolved total pollen proteins from a panel of clinically signi¢-
cant grasses, incubated either with a pool of sera from three grass
pollen-allergic patients or mAb 2A1 in the absence (positive control)
or pre-incubated for 1 h at room temperature in the presence of
potential inhibitors of human IgE/mAb 2A1 binding. In order to
determine the ideal serum and mAb 2A1 dilution where antibodies
were neither in excess or limiting, individual NC strips of SDS^
PAGE-resolved total rye grass pollen proteins were incubated with
the serum pool and mAb 2A1 supernatant at a number of dilutions.
The optimal dilutions were 1:4 for human serum and 1:9 for mAb
2A1. Inhibitors included the 12 amino acid long synthetic peptide
(based on the mimotope sequence, see below; 500 Wg/5 ml/blot) or
crude rye grass pollen extract (150 Wg/5 ml/blot). Detection of anti-
body binding and inclusion of negative controls was the same as that
described above.
2.11. Inhibition ELISA
The method was essentially the same as for the direct ELISA de-
scribed above. However, the rye grass pollen protein-coated wells
were incubated at 37‡C for 1 h with 50 Wl/well with either dilution
of serum or mAb 2A1 that had been pre-incubated with di¡erent
amounts of potential inhibitors for 1 h at room temperature. Inhib-
itors included di¡erent amounts of either puri¢ed mAb 2A1 (to assess
the a¡ect of mAb 2A1 on IgE binding to rye grass pollen extract) or
sera (to assess the e¡ect of IgE on mAb 2A1 binding to rye grass
pollen extract) in a total volume of 50 Wl/well. Other inhibitors in-
cluded synthetic peptide (50 Wg/well) based on the mimotope sequence
(to assess its e¡ect on human IgE/mAb 2A1 binding to rye grass
pollen extract) and rye grass pollen extract (50 Wg/well) as positive
control. Before embarking on these assays, dilution curves for both
the human sera and mAb 2A1 were conducted to determine optimal
dilutions at which the antibodies were neither in excess nor limiting.
The optimal dilutions were 1:200 for human serum and 1:400 for
mAb 2A1. Detection of antibody binding and inclusion of negative
controls (blank) was the same as described for ELISA above. Percent-
age inhibition was calculated by the following formula:
% Inhibition  1003 Absorbance value with inhibitor
Absorbance value without inhibitor
U100
 
C
Fig. 1. Inhibition of mAb 2A1 reactivity by sera from atopic indi-
viduals. A: Inhibition of mAb 2A1 binding to total proteins of rye
grass pollen by individual patient sera. Percentage inhibition of
mAb 2A1 (diluted 1:400) is shown on the y-axis and the amount
(Wl/well) of neat individual serum, used as the potential inhibitor, is
shown on the x-axis. A serum pool of three non-atopic individuals
was used as a negative control. B: Inhibition of human serum IgE
binding to total proteins of rye grass pollen by mAb 2A1. Percent-
age inhibition of human serum IgE (diluted 1:200) is shown on the
y-axis and the amount (Wg/well) of mAb 2A1, used as the potential
inhibitor, is shown on the x-axis. The e¡ect of mAb 2A1 on IgE
binding, from the serum pool of three non-atopic individuals, was
used as a negative control.
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3. Results
3.1. Inhibition ELISA characterisation of mAb 2A1
Among 10 mice injected with equal amounts of Bermuda,
rye and timothy grass pollen extracts, a test bleed of one
mouse demonstrated reactivity to several grass pollens of clin-
ical signi¢cance. This mouse was chosen to clone a mAb-pro-
ducing hybridoma cell line, 2A1, that recognised the panel of
clinically signi¢cant grass pollen allergens.
The mAb 2A1 was puri¢ed and used in a number of im-
munological studies to characterise its speci¢city. We ¢rst
wanted to establish whether mAb 2A1 recognises the same
epitope(s) as human IgE on the di¡erent grass pollen aller-
gens. Therefore, we performed inhibition ELISAs to assess
whether serum of grass pollen allergic patients can inhibit
mAb 2A1 binding to rye grass pollen extract. Among three
atopic individuals, signi¢cant inhibition of mAb 2A1 binding
occurred, while no signi¢cant inhibition was observed when a
serum pool from three non-atopic negative controls was used
(Fig. 1A). Conversely, we assessed the capacity of mAb 2A1
to inhibit human IgE binding to rye grass pollen allergens.
Once again, we showed that mAb 2A1 can signi¢cantly inhibit
human IgE binding to rye grass pollen allergens among the
same three grass pollen-allergic patients (Fig. 1B). The highest
inhibition of IgE binding to rye grass pollen extract by mAb
2A1 was observed with serum of subject 2, followed by 1 and
3 (Fig. 1B).
3.2. Biopanning of a phage-displayed peptide library and
mimotope identi¢cation of mAb 2A1
As a result of mAb 2A1’s capacity to inhibit human IgE
binding to rye grass pollen extracts, we next wanted to iden-
tify the allergen mimotope that was responsible for both mAb
Fig. 2. Mimotope sequence analysis. A: Alignment and sequence of
phage-displayed peptides selected by the mAb 2A1. The sequences
of the peptides were subjected to the multiple alignment algorithm
PILEUP which produces a guide tree indicating the degree of simi-
larity of the peptides to each other and aligns the sequences. The
residues that were identical to those in the frequently selected pep-
tide are in bold and conservatively substituted residues are in bold
italics. B: Alignment of the mimotope sequence with the primary se-
quence of Lol p 1. The positions of Lol p 1 with which residues of
the mimotope sequence align are given in superscript and the amino
acids that were speci¢cally selected for by the mAb 2A1 are boxed.
The arrow indicates insertion of a gap in the sequence of Lol p 1
to optimise the alignment by PILEUP.
Fig. 3. Inhibition of mAb and serum IgE reactivity by the peptide
mimotope. A: Inhibition of mAb 2A1 binding to total proteins of
rye grass pollen by synthetic peptide mimotope and total rye grass
pollen proteins. Absorbance (at 492 nm) for antibody binding is
shown on the y-axis and the antibody binding in the absence (left
bar) and presence of the inhibitors synthetic peptide mimotope
(middle bar) and total rye grass pollen proteins (right bar) is shown
on the x-axis. Percentage inhibition of mAb binding by the respec-
tive inhibitors is indicated by percentage ¢gures on the bars. Omis-
sion of the mAb 2A1 incubation step was included as a negative
control and deducted from the ¢nal readings. B: Inhibition of hu-
man serum IgE binding to total proteins of rye grass pollen by syn-
thetic peptide mimotope and total rye grass pollen proteins (used as
a positive control). Absorbance (at 492 nm) for antibody binding is
shown on the y-axis and the antibody binding in the absence (S;
left bars) and presence of the inhibitors synthetic peptide mimotope
(SP; middle bars) and total rye grass pollen proteins (SE; right
bars) is shown on the x-axis for each of the three individual sera.
Percentage inhibition of human IgE binding by the respective inhibi-
tors is indicated by percentage ¢gures on the bars. Omission of the
serum incubation step was included as a negative control and de-
ducted from the ¢nal readings.
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2A1 and human IgE binding. Identi¢cation of such a mimo-
tope could then facilitate the production of synthetic mimo-
topes that can be used to further investigate inhibition of
mAb 2A1 and human IgE binding to rye grass pollen extract.
After biopanning, 10 individual clones were randomly chos-
en and the DNA insert sequenced. The deduced amino acid
sequences of the 10 clones are given in Fig. 2. Four of the
clones shared 100% amino acid sequence identity with each
other over the 12-amino acid peptide length (Fig. 2A). The
remaining six clones contained some but not all of the amino
acid residues.
3.3. Mimotope sequence analysis
Database comparison of the amino acid sequences of each
clone did not reveal any signi¢cant homologies to known
allergens. Comparison of the frequency of amino acids in
the sequences of the 10 peptides derived from the phage-dis-
played library by the mAb 2A1 with those of peptides from
the naive library reveals that the hydroxyl-containing residues
(serine and threonine; P = 0.0154), glycine (P6 0.001) and
histidine (P = 0.0116) were speci¢cally selected for biopanning
with 2A1. This indicates that these amino acids are likely to
participate in forming the epitope for 2A1. Alignment of the
sequence of the most frequently selected mimotope with the
sequence of Lol p 1 showed that the ¢rst four residues of the
mimotope are identical to amino acids 20^24 of Lol p 1 whilst
residues 7^12 of the mimotope contain four identical residues
to amino acids 53^57 of Lol p 1 (Fig. 2B). Meaningful align-
ments with other allergens (i.e. Lol p 5) were not found. Thus,
whilst there was no similarity found between the mimotope
and continuous stretches of amino acids of allergens present
in the protein database, it is likely that the mimotope repre-
sents a conformational epitope of group 1 allergens, including
Lol p 1, that is formed by the juxtaposition on the surface of
amino acids of Lol p 1 from 20^24 and 53^57, in particular
serine, threonine, glycine and histidine. Indeed, Lol p 1 (20^
24) and Lol p 1 (53^57) sequences are conserved among other
group 1 grass pollen allergens. Therefore, this peptide was
chosen for further immunological studies as outlined below.
3.4. Inhibition ELISA characterisation of synthetic peptide
mimotope
A 12-mer peptide, based on the mimotope amino acid se-
quence (i.e. SAHGTSTGVRGP), was synthesised and used as
an inhibitor in inhibition ELISA immunoassays to assess its
capacity to inhibit mAb 2A1 and human IgE binding to rye
grass pollen extract. When compared with mAb 2A1 binding
in the absence of an inhibitor, pre-incubation of the same
amount of mAb 2A1 with 50 Wg of mimotope peptide showed
76.4% inhibition (Fig. 3A), suggesting that this mimotope se-
quence functionally mimics the natural epitope recognised by
the mAb 2A1. Pre-incubation of mAb 2A1 with 50 Wg of total
rye grass pollen extract (as a positive control) gave 99.8%
inhibition (Fig. 3A).
When sera of the three atopic patients were incubated with
50 Wg of either the mimotope peptide or total rye grass pollen
extract and compared to total IgE binding in the absence of
an inhibitor, the highest inhibition with both the mimotope
peptide (47.3%) and the rye grass pollen extract (65.9%) was
observed with serum of subject 2 (Fig. 3B), which correlates
highly with the earlier inhibition studies using mAb 2A1 as
the inhibitor (Fig. 1B). The next highest inhibition of IgE
binding to rye grass pollen extract by the mimotope peptide
was observed with serum of subject 1 followed by 3 (Fig. 3B),
once again correlating with earlier results (Fig. 1B). Thus, the
mimotope represents an epitope that is recognised by human
IgE from allergic subjects.
We also tested synthetic peptides corresponding to the re-
Fig. 4. Inhibition immunoblot analysis of mAb 2A1 binding to grass and birch pollen extracts. A: SDS^PAGE-resolved protein pro¢les of clin-
ically signi¢cant grass pollens and birch pollen (used as a negative control) stained with Coomassie brilliant blue. mAb 2A1 binding in the ab-
sence of inhibitors (B) or in the presence of synthetic peptide mimotope (500 Wg) (C) or total rye grass pollen proteins (150 Wg) (D). Molecular
mass markers (M) are indicated on the left in kDa. Di¡erent lanes contain total proteins from rye grass (lane 1), Bermuda grass (lane 2), John-
son grass (lane 3), orchard grass (lane 4), velvet grass (lane 5), Kentucky bluegrass (lane 6), meadow fescue (lane 7), timothy grass (lane 8) and
birch pollens (lane 9).
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maining six mimotope sequences (Fig. 2A) by direct ELISA
using ELISA plate-bound peptides. Human IgE binding was
only detected with the peptide corresponding to mimotope 1
(Fig. 2A) with sera of all three atopic patients while no bind-
ing was detected with the serum pool of non-atopic patients
(data not shown).
3.5. Inhibition immunoblot characterisation of synthetic peptide
mimotope
In order to assess and visualise the inhibition of mAb 2A1
and human IgE binding, by the mimotope peptide, to aller-
gens of eight grass and one tree pollens, we used an inhibition
immunoblotting assay. Fig. 4A shows the protein pro¢le of
the nine clinically signi¢cant pollens. Although we aimed to
load the exact amounts of crude pollen proteins in each well,
some samples may look a little faint due to their concentra-
tion being limited by the volume capacity of the gel sample
well. In the absence of inhibitors, mAb 2A1 recognises a
number of proteins of several grasses belonging to group 1
and possibly to group 5 allergens based on the speci¢city of
group 1- and group 5-speci¢c mAbs (data not shown) and
their molecular masses (Fig. 4B). On the other hand, pre-in-
cubation of mAb 2A1 with the mimotope peptide causes sig-
ni¢cant inhibition to the same proteins (Fig. 4C). It is inter-
esting to note that in Fig. 4C, broad bands appear after
incubation of mAb 2A1 with the mimotope peptide. The
most likely reason for this may be the long development
time (in order to ensure that inhibition has occurred) contrib-
uting to the high background development and therefore
smearing or fusing the speci¢c bands together. Pre-incubation
of mAb 2A1 with rye grass pollen extract (positive control)
completely inhibits antibody binding not only to rye grass
pollen extract but also to the other grass pollen proteins,
further highlighting the presence of shared epitope speci¢city
among di¡erent grass pollens (Fig. 4D). Incubation of a rep-
licate blot with detection antibodies only (no-mAb 2A1 neg-
ative control) did not show any antibody binding (data not
shown).
In a similar experiment looking at the inhibition of human
IgE antibody binding (using a serum pool of the three atopic
patients), total IgE binding to the same proteins (Fig. 5A) is
signi¢cantly inhibited by the mimotope peptide (Fig. 5B). It is
interesting to note that in inhibition ELISA the inhibition was
relatively partial even in the presence of 1 mg/ml of the in-
hibitor (Fig. 3B) while the immunoblotting was almost com-
pletely inhibited by 150 Wg/ml (Fig. 5B). A possible reason for
this observation may be that both the conformation epitope-
speci¢c antibodies and primary sequence epitope-speci¢c anti-
bodies can be detected in ELISA while only the latter anti-
bodies can be detected in Western blotting analysis. Total rye
grass pollen extract nearly completely inhibited total IgE
binding (Fig. 5C). Incubation of replicate blots with either
serum from a non-atopic patient or detection antibodies
only (no-serum negative control) did not show any antibody
binding (data not shown). These results further con¢rm that
the identi¢ed mimotope binds both mAb 2A1 and human IgE
and the epitope it represents occurs among related allergens of
di¡erent grass pollens. Moreover, as a result of successful in-
hibition to natural proteins, the mimicked epitope appears to
be surface-exposed and occur as a discontinuous epitope with-
in the context of the natural proteins.
4. Discussion
One of the most critical factors of type I allergic responses
is cross-linking of IgE antibodies on basophils and mast cells,
leading to degranulation and release of chemical mediators. A
better understanding of the molecular basis of human IgE^
allergen interaction could lead to new ways to produce syn-
thetic molecules as ‘blockers’ which may be bene¢cial for
allergy treatment.
As a result of cloning and primary structure determination,
B and T cell epitopes have already been mapped for many
major allergens. However, no major advances in allergy treat-
ment have resulted from such work. On the other hand,
although there has been great interest, very little work has
been reported on the cloning and characterisation of the epi-
topes recognised by human IgE mAbs. With advances in re-
combinant DNA technology, allergen-speci¢c human mAbs
have been studied recently using phage display technology
[16]. A lack of cross-reactivity has been observed between
the native and recombinant Fab of human IgE [16].
Another attractive approach is to produce allergen-speci¢c
murine mAbs that recognise the same epitopes as human IgE
and therefore inhibit human IgE^allergen interaction. Such
mAbs could in principle be used on their own for allergy
treatment, but studies have shown that non-humanised mur-
Fig. 5. Inhibition immunoblot analysis of human IgE binding to
grass and birch pollen extracts. Pooled human serum IgE binding in
the absence of inhibitors (A) or in the presence of synthetic peptide
mimotope (500 Wg) (B) or total rye grass pollen proteins (150 Wg)
(C). Lanes 1^9 are the same as described in Fig. 4.
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ine antibodies are incompatible with the human immune sys-
tem [17]. A great deal of research and resources has been put
into humanising of such antibodies [17]. An alternative ap-
proach is to identify epitopes for such mAbs and investigate
if these inhibit human IgE^allergen interaction. We have ob-
tained such an allergen-speci¢c mAb and report here the iden-
ti¢cation of a mimotope of its epitope using a phage-displayed
peptide library.
The allergen-speci¢c mAb 2A1 inhibits human IgE binding
to rye grass pollen extract, and human IgE inhibits mAb 2A1
binding to the rye grass pollen extract. This demonstrates the
presence of conserved epitope speci¢city between human IgE
and mAb 2A1. Using a phage-displayed peptide library, we
screened mAb 2A1 to identify allergen mimotopes, and iden-
ti¢ed a 12-mer motif which occurs in 40% of the phage clones
sequenced. Screening of the amino acid sequence against the
protein database revealed no signi¢cant linear identity with
any allergens sequenced to date. However, alignment of the
sequence of the mimotope with sequenced allergens of rye
grass pollen revealed patches of identity between parts of
the mimotope and discontinuous regions of Lol p 1 and these
regions of Lol p 1 were conserved among other group 1 grass
pollen allergens. Thus, the phage-displayed peptide may rep-
resent a discontinuous, surface-exposed epitope comprising
amino acids from di¡erent regions of the primary sequence
that are brought together by the particular folding of the
natural protein. We have recently reported that it is possible
for phage-displayed peptides selected by a particular antibody
to mimic discontinuous epitopes that are dependent upon
protein conformation [18].
A peptide based on the 12-mer mimotope was synthesised
and shown to inhibit binding of both mAb 2A1 and human
IgE to rye grass pollen extract. This highlights that the iden-
ti¢ed mimotope corresponds to an epitope recognised by both
mAb 2A1 and human IgE from atopic individuals. In order to
assess if such a mimotope peptide inhibits mAb 2A1 and
human IgE binding to clinically signi¢cant grass and tree
pollens, we performed inhibition immunoblotting assays. Sig-
ni¢cant mAb 2A1 and human IgE binding were observed with
most of the pollens and with several of the major allergens of
these pollens. Although there is signi¢cant evidence for the
existence of allergen homologues in di¡erent grass pollens
[7], this highlights the conservation of this 12-mer epitope
among similar allergens present in the di¡erent pollens.
The presence of such similar allergenic epitopes may sim-
plify both diagnosis and treatment. A cross-reacting range of
mimotopes may be su⁄cient for diagnosis. It is now impor-
tant to assess the e⁄cacy of the peptide we have described in a
population of grass pollen-allergic patients.
Recently another group reported the use of a phage display
peptide library to screen a house dust mite (Der p 1) allergen-
speci¢c murine mAb, which was shown to inhibit human IgE^
Der p 1 interaction [10]. As in our studies, the interaction
between the mAb and Der p 1 can be blocked by the mAb-
speci¢c phage clones. In contrast to our data, inhibition of
human IgE binding to Der p 1 was not demonstrated with the
identi¢ed mimotope [10]. Also, phage clones displaying the
peptide mimotope were used, rather than the synthetic peptide
molecule. Since the three-dimensional model of Der p 1 has
previously been published [10], the authors could successfully
locate the phage-displayed mimotope on the surface of Der p
1 by automated comparative modelling [10]. Unfortunately,
no such three-dimensional models exist for grass pollen aller-
gens that would allow us to locate the phage-displayed mim-
otope. Judging from the Der p 1 studies above, and the ho-
mology with patches of Lol p 1, the mimotope identi¢ed here
may also be surface-exposed on grass pollen allergens. A com-
parison of three-dimensional structures of other cysteine pro-
teases (i.e. chymopapain, papain and actinidin, which are also
recognised by the Der p 1-speci¢c mAb) revealed similar motif
sequences, highlighting the importance of structure-based im-
munological cross-reactivity [10].
This is the ¢rst report that a synthetic peptide of a grass
pollen mimotope blocks the allergen^mAb interaction and
also allergen^human IgE interaction. Current e¡orts are
now directed at the detailed analysis of reactivity and dose^
response inhibitory capacity of the peptide mimotope among
larger atopic and non-atopic patient groups. Moreover, it
would be important to assess if the peptide induces allergic
reactions in vivo (i.e. basophil histamine release). Such collec-
tive novel information may lead to new ways to block aller-
gen^human IgE interactions to provide speci¢c therapy of
allergic diseases.
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